DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of ...
A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...
The accompanying press release dated July 30, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results